JIPANG研究五年总生存分析:培美曲塞或长春瑞滨联合顺铂用于已切除II-IIIA期非鳞非小细胞肺癌
JIPANG研究是一项开放标签III期试验,比较培美曲塞联合顺铂(PemP)与长春瑞滨联合顺铂(NP)作为II-IIIA期非鳞非小细胞肺癌术后辅助化疗的疗效。804例入组患者中783例符合条件(NP组384例,PemP组389例)。中位随访77.3个月时,两组3年和5年总生存率相似,风险比为1.04(95%CI 0.81-1.34),PemP在无复发生存和总生存方面与NP疗效相似。
要点
- PemP组与NP组5年OS率分别为75.0%与75.6%,HR 1.04(95%CI 0.81-1.34)。
- PemP组与NP组中位RFS分别为43.4个月与37.5个月,HR 0.95(95%CI 0.79-1.14)。
- 长期随访显示PemP在RFS和OS方面与NP疗效相似。
核心结论
- 长期随访分析显示,在II-IIIA期非鳞非小细胞肺癌术后辅助化疗中,PemP在RFS和OS方面与NP疗效相似。
研究设计与样本
- JIPANG研究是一项开放标签III期试验,评估培美曲塞联合顺铂(PemP)对比长春瑞滨联合顺铂(NP)作为II-IIIA期非鳞非小细胞肺癌术后辅助化疗的疗效。
- 共入组804例患者,其中783例符合条件(NP组384例,PemP组389例),随机分配至PemP或NP组。
- 主要终点为无复发生存(RFS),次要终点包括总生存(OS)。
- 本次分析使用最后一位患者入组后5年收集的数据。
主要发现
- 更新中位RFS:NP组37.5个月 vs PemP组43.4个月,风险比(HR)0.95(95%CI 0.79-1.14)。
- 中位随访77.3个月时,3年和5年OS率:NP组84.1%和75.6% vs PemP组87.0%和75.0%,HR 1.04(95%CI 0.81-1.34)。
- 该长期随访分析显示,PemP在RFS和OS方面与NP疗效相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The JIPANG study is an open-label phase III trial evaluating the efficacy of pemetrexed plus cisplatin (PemP) versus vinorelbine plus cisplatin (NP) as adjuvant chemotherapy in patients with stage II-IIIA nonsquamous non-small-cell lung cancer (NSCLC). Here, we report the long follow-up overall survival (OS) data. Eligible patients were randomly assigned to receive either PemP or NP. The primary end point was recurrence-free survival (RFS), and the secondary end point included OS. This analysis was performed using data collected 5 years after the last patient enrollment. Among 804 patients enrolled, 783 patients were eligible (384 for NP and 389 for PemP). The updated median RFS was 37.5 months in the NP arm and 43.4 months in the PemP arm with a hazard ratio of 0.95 (95% CI, 0.79 to 1.14). At a median follow-up of 77.3 months, the OS rates at 3 and 5 years were 84.1% and 75.6% versus 87.0% and 75.0% with a hazard ratio of 1.04 (95% CI, 0.81 to 1.34). This long-term follow-up analysis showed that PemP had similar efficacy to NP in both RFS and OS for this population, with one of the longest OS data compared with the historical data.
引用
- Kenmotsu H, Yamamoto N, Misumi T, et al. Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37656928. doi:10.1200/JCO.23.00179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。